Generic Oxecta Availability

Oxecta is a brand name of oxycodone, approved by the FDA in the following formulation(s):

OXECTA (oxycodone hydrochloride - tablet;oral)

  • Manufacturer: ACURA PHARMS INC
    Approval date: June 17, 2011
    Strength(s): 5MG, 7.5MG

Has a generic version of Oxecta been approved?

No. There is currently no therapeutically equivalent version of Oxecta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxecta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods and compositions for deterring abuse of opioid containing dosage forms
    Patent 7,201,920
    Issued: April 10, 2007
    Inventor(s): Kumar; Vijai & Dixon; David & Tewari; Divya & Wadgaonkar; Dilip B.
    Assignee(s): Acura Pharmaceuticals, Inc.
    This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Patent expiration dates:
    • March 16, 2025
      ✓ 
      Drug product
  • Methods and compositions for deterring abuse of opioid containing dosage forms
    Patent 7,510,726
    Issued: March 31, 2009
    Inventor(s): Kumar; Vijai & Dixon; David & Tewari; Divya & Wadgaonkar; Dilip B.
    Assignee(s): Acura Pharmaceuticals, Inc.
    This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Patent expiration dates:
    • November 26, 2023
      ✓ 
      Drug product
  • Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
    Patent 7,981,439
    Issued: July 19, 2011
    Inventor(s): Kumar; Vijai & Dixon; David & Tewari; Divya & Wadgaonkar; Dilip B.
    Assignee(s): Acura Pharmaceuticals, Inc.
    This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Patent expiration dates:
    • November 26, 2023
      ✓ 
      Drug product
  • Extended release opioid abuse deterrent compositions and methods of making same
    Patent 8,409,616
    Issued: April 2, 2013
    Assignee(s): Acura Pharmaceuticals, Inc.
    This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Patent expiration dates:
    • November 26, 2023
      ✓ 
      Drug product
  • Compositions for deterring abuse of opioid containing dosage forms
    Patent 8,637,540
    Issued: January 28, 2014
    Assignee(s): Acura Pharmaceuticals
    This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Patent expiration dates:
    • November 26, 2023
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide
(web3)